Antimicrobial peptides (AMPs) are part of the innate immune defense mechanism of many
organisms. Although AMPs have been essentially studied and developed as potential …

In the last several decades, there have been significant advances in anticancer therapy.
However, the development of resistance to cancer drugs and the lack of specificity related to …

Although much progress has been achieved in the development of cancer therapies in
recent decades, problems continue to arise particularly with respect to chemotherapy due to …

The interaction of antimicrobial peptides (AMPs) with biological membranes is in the focus of
research since several years, and the most important features and modes of action of AMPs …

Mycoses are accountable for millions of infections yearly worldwide. Invasive candidiasis is
the most usual, presenting a high morbidity and mortality. Candida albicans remains the …

There is an ongoing need for effective and targeted cancer treatments that can overcome the
detrimental side effects presented by current treatment options. One class of novel …

Here, we review potential determinants of the anticancer efficacy of innate immune peptides
(ACPs) for cancer cells. These determinants include membrane‐based factors, such as …

Acquired drug resistance is the major cause for disease recurrence in cancer patients, and
this is particularly true for patients with metastatic melanoma that carry a BRAF V600E …

Several cationic antimicrobial peptides (AMPs) have recently been shown to display
anticancer activity via a mechanism that usually entails the disruption of cancer cell …

Many active principles produced by animals, plants and microorganisms have been
employed in the development of new drugs to treat diseases such as cancer. Among the …